LLY

716.57

-4.43%↓

JNJ

146.27

-2.06%↓

UNH

311

-1.42%↓

ABBV

178.8

-5.55%↓

NVO

64.13

-1.81%↓

LLY

716.57

-4.43%↓

JNJ

146.27

-2.06%↓

UNH

311

-1.42%↓

ABBV

178.8

-5.55%↓

NVO

64.13

-1.81%↓

LLY

716.57

-4.43%↓

JNJ

146.27

-2.06%↓

UNH

311

-1.42%↓

ABBV

178.8

-5.55%↓

NVO

64.13

-1.81%↓

LLY

716.57

-4.43%↓

JNJ

146.27

-2.06%↓

UNH

311

-1.42%↓

ABBV

178.8

-5.55%↓

NVO

64.13

-1.81%↓

LLY

716.57

-4.43%↓

JNJ

146.27

-2.06%↓

UNH

311

-1.42%↓

ABBV

178.8

-5.55%↓

NVO

64.13

-1.81%↓

Search

Sana Biotechnology Inc

Avatud

SektorTervishoid

1.79 -2.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.79

Max

1.89

Põhinäitajad

By Trading Economics

Sissetulek

-320K

-49M

Aktsiakasum

-0.2

Töötajad

194

EBITDA

12M

-45M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+262.5% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

25M

451M

Eelmine avamishind

3.98

Eelmine sulgemishind

1.79

Uudiste sentiment

By Acuity

50%

50%

209 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2025, 23:20 UTC

Tulu

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. mai 2025, 22:58 UTC

Tulu

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. mai 2025, 22:37 UTC

Tulu

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. mai 2025, 22:36 UTC

Tulu

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. mai 2025, 22:35 UTC

Tulu

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. mai 2025, 22:34 UTC

Tulu

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. mai 2025, 22:30 UTC

Tulu

Aristocrat Interim Dividend 44 Australian Cents/Share

13. mai 2025, 22:30 UTC

Tulu

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. mai 2025, 22:29 UTC

Tulu

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. mai 2025, 22:28 UTC

Tulu

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. mai 2025, 21:15 UTC

Tulu

Nu Holdings 1Q Rev $3.2B >NU

13. mai 2025, 21:03 UTC

Peamised uudised

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. mai 2025, 20:32 UTC

Tulu

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. mai 2025, 20:31 UTC

Tulu

Alcon 1Q Sales $2.45B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q Rev $2.47B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q EPS 70c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

262.5% tõus

12 kuu keskmine prognoos

Keskmine 7.25 USD  262.5%

Kõrge 11 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

209 / 382 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.